Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cancer Commun (Lond). 2019 Nov 9;39(1):72. doi: 10.1186/s40880-019-0418-0.

Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.

Author information

1
University of Arizona Cancer Center, Tucson, AZ, 85724, USA.
2
Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona, Tucson, AZ, 85721, USA.
3
Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, 85721, USA.
4
Arizona Center for Drug Discovery, Tucson, AZ, 85721, USA.
5
University of Arizona Cancer Center, Tucson, AZ, 85724, USA. jcarew@email.arizona.edu.
6
Division of Translational and Regenerative Medicine, Department of Medicine, University of Arizona, Tucson, AZ, 85721, USA. jcarew@email.arizona.edu.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center